Active	Status	Sponsor type	Region	Phase	Filter
7 Active 6 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Adam
NCT03452202: Using tDCS in Speech-based Stroke Rehabilitation	Recruiting	N/A	24	US	Soterix 1x1 line tDCS low-intensity stimulator, Soterix, Sham	NYU Langone Health, National Institute on Deafness and Other Communication Disorders (NIDCD)	Apraxia of Speech	10/26	10/26
Maher, James
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial Feb 2024 - Dec 2024 : Data from SUMMIT trial in participants with heart failure with preserved ejection fraction and obesity	Completed	3	731	US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)	07/24	07/24
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	3	160	Europe, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic	08/24	09/25
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis	Recruiting	3	1063	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis	07/26	12/27
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet	Completed	2	153	Europe, Canada, US	TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar	Takeda	Celiac Disease	11/24	11/24
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode	Active, not recruiting	N/A	44467	US		Guardant Health, Inc., Premier Research Group plc	Colorectal Cancer	03/24	12/25
NCT05257551: Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study	Recruiting	N/A	50	US	Observation	Tempus AI, AstraZeneca	Small Cell Lung Cancer	03/26	03/26